Previous Close | 1.9600 |
Open | 1.9800 |
Bid | 1.8500 x 4000 |
Ask | 1.8900 x 2200 |
Day's Range | 1.8200 - 1.9800 |
52 Week Range | 1.4500 - 6.3200 |
Volume | |
Avg. Volume | 1,486,480 |
Market Cap | 310.186M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3990 |
Earnings Date | Nov 10, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.58 |
Subscribe to Yahoo Finance Plus to view Fair Value for ATAI
HC Wainwright lowered the price target for Atai Life Sciences N.V. (NASDAQ: ATAI) from $50 to $20 to reflect recent adverse outcomes in programs such as PCN-101 in treatment-resistant depression and KUR-101 in opioid use disorder. Most recently, Atai Life Sciences-owned Perception Neuroscience announced that the Phase 2a trial of PCN-101 (R-ketamine) did not meet its primary endpoint of a statistically significant change from baseline in participants' depression rating scale score at 24 hours co
When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scie...
Key Takeaways; Cannabis Sector Leafly Holdings started the year with strong market performance. Innovative Industrial Properties’ market performance remained robust, following the announcement of significant dividends for 2022. Columbia Care subsidiary is carrying out large-scale cannabis industry layoffs. Key Takeaways; Psychedelic Sector Awakn’s ketamine-assisted psychotherapy for the treatment of AUD was ranked as the 5th […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector